|
2025 Journal Article The effect of oral colchicine and vitamin K1 on bone metabolism in patients with diabetes mellitus: A post-hoc analysis of a 2 × 2 factorial randomized controlled trial with 18F-sodium fluoride positron emission tomographyBellinge, Jamie W., Sim, Marc, Francis, Roslyn J., Lee, Sing Ching, Chan, Dick C., Girgis, Christian M., Watts, Gerald F., Lewis, Joshua R. and Schultz, Carl J. (2025). The effect of oral colchicine and vitamin K1 on bone metabolism in patients with diabetes mellitus: A post-hoc analysis of a 2 × 2 factorial randomized controlled trial with 18F-sodium fluoride positron emission tomography. Bone, 196 117492, 117492. doi: 10.1016/j.bone.2025.117492 |
|
2025 Journal Article Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialKwan, Edmond M., Ng, Sarah W. S., Tolmeijer, Sofie H., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Donnellan, Grainne, Annala, Matti, Herberts, Cameron, Davis, Ian D., Hofman, Michael S., Azad, Arun A., Wyatt, Alexander W., Akhurst, Tim, Alipour, Ramin, Bailey, Dale L., Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Chua, Wei, Crumbaker, Megan ... Zhang, Alison Y. (2025). Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nature Medicine, 1-15. doi: 10.1038/s41591-025-03704-9 |
|
2025 Journal Article Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA StudyChen, David C., Buteau, James P., Emmett, Louise, Alipour, Ramin, de Galiza Barbosa, Felipe, Roberts, Matthew J., McVey, Aoife, O’Brien, Jonathan, Levy, Sidney, Francis, Roslyn J., Lawrentschuk, Nathan, Murphy, Declan G. and Hofman, Michael S. (2025). Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study. Journal of Nuclear Medicine, 66 (5), 713-718. doi: 10.2967/jnumed.124.268901 |
|
2025 Journal Article Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST studyFielding, David, Sidhu, Calvin, Alkhater, Mahmoud, Alawami, Moayed, Kops, Stephan E P, van der Heijden, Erik H F M, Bashirzadeh, Farzad, Windsor, Morgan, Nixon, Elizabeth, Son, Jung Hwa, Ananda Setty, Niranjan, Pattison, David A, Fong, William, Bhatt, Manoj, Dhiantravan, Nattakorn, Ramsay, Stuart, Boots, Robert, Putt, Michael, Pratt, Gary, Bettington, Catherine, Francis, Roslyn, Thomas, Paul, Steinke, Karin and Thomas, Rajesh (2025). Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST study. BMJ Open Respiratory Research, 12 (1) e002553, e002553. doi: 10.1136/bmjresp-2024-002553 |
|
2025 Journal Article An External, Independent Validation of an<i>O</i>-(2-[<sup>18</sup>F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with GlioblastomaBarry, Nathaniel, Kendrick, Jake, Rowshanfarzad, Pejman, Hassan, Ghulam Mubashar, Francis, Roslyn J., Bucknell, Nicholas, Koh, Eng-Siew, Scott, Andrew M., Ebert, Martin A., Gutsche, Robin, Ciantar, Keith George, Galldiks, Norbert, Langen, Karl-Josef and Lohmann, Philipp (2025). An External, Independent Validation of anO-(2-[18F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma. Journal of Nuclear Medicine, 66 (6), jnumed.124.268925-953. doi: 10.2967/jnumed.124.268925 |
|
2025 Conference Publication Overall survival and quality of life with [ <sup>177</sup> Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901)Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew James, Lee, Sze Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian David, Sandhu, Shahneen, Zhang, Alison Yan, Hofman, Michael S., Thomas, Hayley, Martin, Andrew James, Davis, Ian D., Stockler, Martin R. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). Overall survival and quality of life with [ 177 Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901). 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.17 |
|
2025 Journal Article Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9 |
|
2025 Journal Article Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET/CTMolin, Kaylee, Barry, Nathaniel, Gill, Suki, Hassan, Ghulam Mubashar, Francis, Roslyn J., Ong, Jeremy S. L., Ebert, Martin A. and Kendrick, Jake (2025). Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET/CT. Physical and Engineering Sciences in Medicine, 48 (1), 329-341. doi: 10.1007/s13246-024-01516-8 |
|
2025 Journal Article Fluorodeoxyglucose Positron Emission Tomography Detects Persistent Arterial Inflammation After Symptomatic COVID-19Espedal, Heidi, Verma, Shipra, Roy, Ambuj, Lan, Nick S.R., Mohd, Sheeraz, Bartlett, Benjamin, Ali, Kamar, Ward, Natalie C., Ebert, Martin A., Chan, Dick C., Watts, Gerald F., Dwivedi, Girish and Francis, Roslyn J. (2025). Fluorodeoxyglucose Positron Emission Tomography Detects Persistent Arterial Inflammation After Symptomatic COVID-19. Heart Lung and Circulation. doi: 10.1016/j.hlc.2025.03.005 |
|
2025 Journal Article Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccineThunold, Solfrid, Hernes, Eivor, Farooqi, Saima, Öjlert, Åsa Kristina, Francis, Roslyn J., Nowak, Anna K., Szejniuk, Weronika Maria, Nielsen, Søren Steen, Cedres, Susana, Perdigo, Marc Simo, Sørensen, Jens Benn, Meltzer, Carin, Mikalsen, Lars Tore Gyland, Helland, Åslaug, Malinen, Eirik and Haakensen, Vilde Drageset (2025). Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. European Journal of Nuclear Medicine and Molecular Imaging, 52 (2), 693-707. doi: 10.1007/s00259-024-06853-0 |
|
2024 Conference Publication Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell LymphomaLewis, Katharine L., Giri, Pratyush, Marconi, Tamara, Blombery, Piers, Keane, Colm, Sungala, Nagendra Prasad, Cochrane, Tara, Ma, Chun Kei Kris, Vanguru, Vinay, Manos, Kate, Francis, Roslyn, Walia, Mannu, Carlson, Julia, Butcher, Belinda E. and Cheah, Chan Y. (2024). Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-204317 |
|
2024 Conference Publication Multi-site, Prospective Trial Evaluating FET-PET In Glioblastoma (FIG) Study (TROG 18.06): Preliminary Results Of Central Nuclear Medicine Review Of FET-PET Biologic Target Volume Delineation For Radiation PlanningKoh, Eng-Siew, Francis, Roslyn, Lee, SzeTing, Lau, Eddie, Thomas, Elizabeth, Whitehead, Angela, Cook, Olivia, Dykyj, Rachael, Moore, Alisha, Rossi, Alana, Thomas, Paul, Pattison, David, Akhurst, Tim, Alipour, Ramin, Hsiao, Edward, Schembri, Geoffrey, Lin, Peter, Yap, June, Ly, Tam, Kirkwood, Ian, Vallat, Wilson, Krishna, Dayanethee Krishna, Khan, Shahroz Khan, Ngai, Stanley Ngai, Yu, Chris, Beuzeville, Scott, Yeow, Tow Chan, Barry, Nathaniel, Ebert, Martin ... Scott, Andrew M. (2024). Multi-site, Prospective Trial Evaluating FET-PET In Glioblastoma (FIG) Study (TROG 18.06): Preliminary Results Of Central Nuclear Medicine Review Of FET-PET Biologic Target Volume Delineation For Radiation Planning. 2024 Society for Neuro-Oncology’s 29th Annual Meeting and Education Day, Houston, TX United States, 21-24 November 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/neuonc/noae165.0806 |
|
2024 Journal Article Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 studyAzad, Arun A, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, Hofman, Michael S, Akhurst, T, Alipour, R, Au, L, Banks, P ... Ratnayake, L (2024). Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. The Lancet Oncology, 25 (10), 1267-1276. doi: 10.1016/s1470-2045(24)00440-6 |
|
2024 Journal Article Assessing the heterogeneity of response of [68Ga] Ga-PSMA-11 PET/CT lesions in patients with biochemical recurrence of prostate cancerDell'Oro, Mikaela, Huff, Daniel T., Lokre, Ojaswita, Kendrick, Jake, Munian Govindan, Rajkumar, Ong, Jeremy S. L., Ebert, Martin A., Perk, Timothy G. and Francis, Roslyn J. (2024). Assessing the heterogeneity of response of [68Ga] Ga-PSMA-11 PET/CT lesions in patients with biochemical recurrence of prostate cancer. Clinical Genitourinary Cancer, 22 (5) 102155, 102155. doi: 10.1016/j.clgc.2024.102155 |
|
2024 Conference Publication A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)Azad, A.A., Bressel, M., Tan, H., Voskoboynik, M., Suder, A., Weickhardt, A.J., Guminski, A., Francis, R.J., Saghebi, J., Dhiantravan, N., Joshua, A., Emmett, L., Murphy, D., Hsiao, E., Lee, S.T., Pattison, D.A., Nadebaum, D., Kirkwood, I.D. and Hofman, M.S. (2024). A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.2309 |
|
2024 Journal Article Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CTParry, R., Wright, K., Bellinge, J. W., Ebert, M. A., Rowshanfarzad, P., Francis, R. J. and Schultz, C. J. (2024). Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT. International Journal of Cardiovascular Imaging, 40 (9), 1847-1861. doi: 10.1007/s10554-024-03171-2 |
|
2024 Journal Article The Australian Traumatic Brain Injury Initiative: systematic review of clinical factors associated with outcomes in people with moderate-severe traumatic brain injuryMcKimmie, Ancelin, Keeves, Jemma, Gadowski, Adelle, Bagg, Matthew K., Antonic-Baker, Ana, Hicks, Amelia J., Hill, Regina, Clarke, Nyssa, Holland, Andrew, Veitch, Bill, Fatovich, Daniel, Reeder, Sandy, Romero, Lorena, Ponsford, Jennie L., Lannin, Natasha A., O’Brien, Terence J., Cooper, D. Jamie, Rushworth, Nick, Fitzgerald, Melinda, Gabbe, Belinda J., Cameron, Peter A., Alexander, Tara, Anderson, Vicki, Armstrong, Elizabeth, Babl, Franz E., Balogh, Zsolt J., Barlow, Karen M. (AUS-TBI Investigators member), Bellapart, Judith, Bidargaddi, Niranjan ... Zeeman, Heidi (2024). The Australian Traumatic Brain Injury Initiative: systematic review of clinical factors associated with outcomes in people with moderate-severe traumatic brain injury. Neurotrauma Reports, 5 (1), 640-659. doi: 10.1089/neur.2023.0111 |
|
2024 Journal Article Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancerButeau, James P., Moon, Daniel, Fahey, Michael T., Roberts, Matthew J., Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, De Abreu Lourenco, Richard, Dhillon, Haryana M., Kasivisvanathan, Veeru, Francis, Roslyn J., Stricker, Phillip, Agrawal, Shihka, O'Brien, Jonathan, McVey, Aoife, Sharma, Gaurav, Levy, Sidney, Ayati, Narjess, Nguyen, Andrew, Lee, Su-Faye, Pattison, David A., Sivaratnam, Dinesh, Frydenberg, Mark, Du, Yang, Titus, Jehan, Lee, Sze-Ting, Ischia, Joseph, Jack, Greg ... Emmett, Louise (2024). Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer. European Urology Oncology, 7 (3), 544-552. doi: 10.1016/j.euo.2023.11.008 |
|
2024 Journal Article An automated radiosynthesis of [68Ga]Ga-FAPI-46 for routine clinical useMorandeau, Laurence, Ioppolo, Joseph A., Alvarez de Eulate, Eva, Mohamed, Shifaza, Cullen, Danica, Asad, Ali H., Francis, Roslyn J. and Atkinson, Janette (2024). An automated radiosynthesis of [68Ga]Ga-FAPI-46 for routine clinical use. Journal of Visualized Experiments, 2024 (207) e66708. doi: 10.3791/66708 |
|
2024 Journal Article [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Gedye, Craig, Rutherford, Natalie K., Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P., Voskoboynik, Mark, Redfern, Andrew D., Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Davis, Ian D. (2024). [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. The Lancet Oncology, 25 (5), 563-571. doi: 10.1016/s1470-2045(24)00135-9 |
